2,5-Dioxopyrrolidin-1-yl 4-hydroxybenzoate, 97%, 100mg

1-Pyridin-2-yl-propan-2-one, 95.0%, 25g

tert-Butyl N-(4-bromopyridin-2-yl)-N-methylcarbamate, 95+%, 250mg

Récepteur à vide avec raccord fileté courbé 105°, 19/26, 19/26, 1 pièce

(R)-3-((tert-Butoxycarbonyl)amino)-2-methylpropanoic acid, 95.0%, 250mg

(R)-3-Amino-4-(4-nitrophenyl)butanoic acid hydrochloride, 95.0%, 250mg

6-Oxo-1-phenyl-1,6-dihydropyridine-3-carboxylic acid, 95.0%, 5g

4-(4-ETHYNYLPHENYL)MORPHOLINE, 95.0%, 250mg

2-Amino-benzothiazol-6-ol, 99.00%, 25g

5-Bromo-1H-1,2,4-triazole-3-carboxylic acid, 95.0%, 1g

4'-(trans-4-propylcyclohexyl)-[1,1'-biphenyl]-4-carbonitrile, 97.0%, 25g

monoclonal de souris anti-GAPDH, clone 6C5, 0,2 ml

Ethyl-2,2-difluorobutyrate, 95.0%, 250mg